CHIKV VLP/adjuvant

BIOLOGICAL2 trials

Sponsors

Bavarian Nordic

Conditions

Chikungunya Virus

Phase 3

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)

CompletedNCT05072080

Bavarian NordicChikungunya Virus

Start: 2021-09-29End: 2023-04-03Updated: 2024-08-30

Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years

CompletedNCT05349617

Bavarian NordicChikungunya Virus

Start: 2022-05-12End: 2023-08-08Updated: 2024-12-13

Related Papers

Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial.

2025-03-2718 citations

Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial.

2025-03-278 citations

2888. Safety and Immunogenicity of an Adjuvanted Chikungunya Virus (CHIKV) Virus-like Particle (VLP) Based Vaccine in Two Pivotal Phase 3 Trials, ≥12 Years of Age

Open Forum Infectious Diseases2023-11-273 citations

Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial.

2022-06-1344 citations